Astrazeneca (AZN) Equity Ratio (2016 - 2025)
Astrazeneca (AZN) has 3 years of Equity Ratio data on record, last reported at 0.43 in Q4 2025.
- For Q4 2025, Equity Ratio rose 8.94% year-over-year to 0.43; the TTM value through Dec 2025 reached 0.43, up 8.94%, while the annual FY2025 figure was 0.43, 8.94% up from the prior year.
- Equity Ratio reached 0.43 in Q4 2025 per AZN's latest filing, up from 0.39 in the prior quarter.
- Across five years, Equity Ratio topped out at 125.13 in Q4 2023 and bottomed at 0.39 in Q4 2024.
- Average Equity Ratio over 3 years is 41.98, with a median of 0.43 recorded in 2025.
- Peak YoY movement for Equity Ratio: crashed 99.69% in 2024, then grew 8.94% in 2025.
- A 3-year view of Equity Ratio shows it stood at 125.13 in 2023, then plummeted by 99.69% to 0.39 in 2024, then increased by 8.94% to 0.43 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.43 in Q4 2025, 0.39 in Q4 2024, and 125.13 in Q4 2023.